CN Stock MarketDetailed Quotes

688319 Chengdu Olymvax Biopharmaceuticals Inc

Watchlist
  • 10.55
  • -0.19-1.77%
Trading Jan 9 10:45 CST
4.28BMarket Cap-502.38P/E (TTM)

Chengdu Olymvax Biopharmaceuticals Inc Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chengdu Olymvax Biopharmaceuticals Inc Q3 2024 Earnings Date

Currency：CNYOct 30, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
--
160.37M
--
+34.65%
EPS
--
0.08
--
--
Analyst Rating
Strong Buy

Jan 8, 2025

Chengdu Olymvax Biopharmaceuticals Inc Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
Date Period Revenue/Estimate Earnings Call
-- 2025/FY -- / 631.000M --
-- 2024/FY -- / 557.000M --
-- 2023/FY 496.119M / 632.763M --
-- 2022/FY 547.481M / 595.000M --
-- 2021/FY 487.303M / 513.000M --
DatePeriodRevenue/EstimateEarnings Call
--2025/FY-- / 631.000M--
--2024/FY-- / 557.000M--
--2023/FY496.119M / 632.763M--
--2022/FY547.481M / 595.000M--
--2021/FY487.303M / 513.000M--

Unlock Free Earnings Estimates

Chengdu Olymvax Biopharmaceuticals Inc Earnings Reports

  • Chengdu Olin Biotechnology Co., Ltd. Report for the Third Quarter of 2024

    Oct 30, 2024 00:00

  • 2024 interim report of Chengdu Olin Biotechnology Co., Ltd.

    Aug 22, 2024 00:00

  • Summary of the 2024 interim report of Olin Biotechnology Co., Ltd. in Chengdu.

    Aug 22, 2024 00:00

  • Summary of the 2023 Annual Report of Chengdu Olin Biotechnology Co., Ltd.

    Apr 26, 2024 00:00

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 8, 2025

    Strong Buy

    • Strong Buy

      83.33%

    • Buy

      16.67%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Specialized, Special and New
    Specialized, Special and New
    Intraday+1.04%